PARP1 and central nervous system cancer: In this study, 24/213 (11%) glioma patients with presumed tumor predisposition carried GVs in CPGs that potentially sensitize them to targeted therapies not routinely used in glioma patients, such as PARP, immune checkpoint, EGFR, or CDK4/6 inhibitors (Fig. 5).